Topical TMB-001 Disappoints in Phase 3 Congenital Ichthyosis Trial
The Dermatology Digest
AUGUST 21, 2024
Food and Drug Administration, according to Leo Pharma and Timber Pharmaceuticals. The trial evaluated the efficacy and safety of TMB-001 in the treatment of congenital ichthyosis in patients (aged 6 or older) with either the autosomal recessive congenital ichthyosis (ARCI) or X-linked recessive ichthyosis (XLRI) subtypes.
Let's personalize your content